We are live on
!
Find out more
SEC
Seven Eight Capital Portfolio holdings
AUM
$1.11B
1-Year Est. Return
29.48%
This Fund
S&P 500
This Quarter
Est. Return
-6.56%
1 Year Est. Return
+29.48%
3 Year Est. Return
+13.61%
5 Year Est. Return
+117.69%
10 Year Est. Return
+239.1%
AUM
$855M
AUM Growth
+$250M
(+41%)
Cap. Flow
+$327M
Cap. Flow
% of AUM
38.29%
Top 10 Holdings %
Top 10 Hldgs %
13.1%
Holding
788
New
316
Increased
155
Reduced
106
Closed
211
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edwards Lifesciences
EW
|
+$13.6M |
| 2 |
Merck
MRK
|
+$12.5M |
| 3 |
Intuitive Surgical
ISRG
|
+$11.1M |
| 4 |
DOCU
DocuSign
DOCU
|
+$10.9M |
| 5 |
Insulet
PODD
|
+$10.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nasdaq
NDAQ
|
+$7.26M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
+$6.86M |
| 3 |
Incyte
INCY
|
+$6.31M |
| 4 |
Fidelity National Information Services
FIS
|
+$5.73M |
| 5 |
AbbVie
ABBV
|
+$4.95M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.41% |
| 2 | Consumer Discretionary | 17.68% |
| 3 | Healthcare | 16.13% |
| 4 | Industrials | 12.13% |
| 5 | Financials | 8.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
526
International Paper
IP
$22.4B
| $251K | 0.03% |
+7,090
| New | +$241K |
|
|
CHX
527
DELISTED
ChampionX
CHX
| $250K | 0.03% |
+7,014
| New | +$249K |
|
528
Valaris
VAL
$5.41B
| $250K | 0.03% |
+3,330
| New | +$245K |
|
529
M/I Homes
MHO
$3.8B
| $247K | 0.03% |
+2,944
| New | +$272K |
|
530
Ameren
AEE
$30.3B
| $247K | 0.03% |
3,296
-1,399
| -30% | -$114K |
|
531
Green Plains
GPRE
$1.19B
| $246K | 0.03% |
+8,179
| New | +$268K |
|
532
Cemex
CX
$16.8B
| $246K | 0.03% |
+37,806
| New | +$281K |
|
533
American Water Works
AWK
$26.6B
| $244K | 0.03% |
+1,970
| New | +$276K |
|
534
Automatic Data Processing
ADP
$108B
| $243K | 0.03% |
1,010
-2,612
| -72% | -$637K |
|
535
Southern Company
SO
$107B
| $241K | 0.03% |
3,721
+661
| +22% | +$45.9K |
|
536
Mine Safety
MSA
$7.45B
| $241K | 0.03% |
+1,527
| New | +$262K |
|
537
Phinia Inc
PHIN
$2.93B
| $239K | 0.03% |
+8,928
| New | +$247K |
|
538
Arthur J. Gallagher & Co
AJG
$63.6B
| $236K | 0.03% |
+1,037
| New | +$232K |
|
539
Mettler-Toledo International
MTD
$28.8B
| $236K | 0.03% |
+213
| New | +$261K |
|
540
Check Point Software Technologies
CHKP
$12.7B
| $235K | 0.03% |
1,765
-3,501
| -66% | -$460K |
|
|
541
BioMarin Pharmaceuticals
BMRN
$11.7B
| $235K | 0.03% |
2,653
-77,146
| -97% | -$6.86M |
|
542
Radian Group
RDN
$5.27B
| $235K | 0.03% |
+9,348
| New | +$247K |
|
543
Carter's
CRI
$1.46B
| $234K | 0.03% |
+3,390
| New | +$242K |
|
544
Beam Therapeutics
BEAM
$2.92B
| $234K | 0.03% |
+9,747
| New | +$261K |
|
545
News Corp Class A
NWSA
$15.5B
| $230K | 0.03% |
+11,450
| New | +$232K |
|
546
PACCAR
PCAR
$71.6B
| $230K | 0.03% |
2,700
-17,912
| -87% | -$1.52M |
|
547
Modine Manufacturing
MOD
$10.7B
| $223K | 0.03% |
+4,878
| New | +$205K |
|
548
Expro Ltd
XPRO
$1.88B
| $223K | 0.03% |
+9,582
| New | +$216K |
|
549
Matsons
MATX
$6.46B
| $219K | 0.03% |
+2,474
| New | +$216K |
|
550
Essent Group
ESNT
$6.14B
| $219K | 0.03% |
+4,625
| New | +$229K |
|
Similar funds
PP
ECM
GCAC
CAM
D
GFS
FTIS
AIA
Seven Eight Capital's Q3 2023 Portfolio in Review
As of Q3 2023, Seven Eight Capital held 788 positions worth $855M, up 41% from $605M the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Seven Eight Capital deployed $327M of net new capital in Q3 2023, opening 316 new positions and adding to 155 existing holdings. Its largest new stake was Merck: 115,677 shares worth $11.9M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 22% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $6.86M trimmed.
- Seven Eight Capital's largest Q3 2023 buy was Merck: 115,677 shares worth $11.9M.
- Seven Eight Capital added most to Edwards Lifesciences in Q3 2023, an estimated $13.6M increase.
- Seven Eight Capital's biggest Q3 2023 reduction was BioMarin Pharmaceuticals, cutting an estimated $6.86M.
- Seven Eight Capital fully exited Nasdaq in Q3 2023, selling an estimated $7.26M.
- Seven Eight Capital's ten largest holdings make up 13% of its $855M portfolio in Q3 2023.
- Seven Eight Capital opened 316 new positions and closed 211 in Q3 2023.
- Seven Eight Capital's portfolio value rose 41% quarter-over-quarter to $855M.
Based on Seven Eight Capital's 13F filing for Q3 2023, filed 14 Nov 2023.